Regrettably, these characters did not include molecular analyses and immunological profiles such as PD-L1, VEGFR, PDGFR, tumor mutation burden, and microsatellite instability, which may give us more insight into the relationship between the efficacy of combination therapies and molecular mechanisms. The gene discussed is CD274; the disease is neoplasm.